Novo Nordisk made its most significant commercial move of the year two days before reporting Q1 earnings. The company launched oral Ozempic—a rebrand of the existing Rybelsus (oral semaglutide) under the far more recognizable Ozempic name—in more than 70,000 U.S. pharmacies on Monday. Insured patients pay as little as $25 for a three-month supply. Cash-pay patients using select telehealth providers pay $149 per month for the starter dose. The pills are manufactured entirely in the United States, insulating the supply chain from Section 232 tariff exposure. The timing is clearly intentional. Novo reports Q1 earnings this morning, delivering the first official oral Wegovy revenue numbers and updating 2026 guidance. Meanwhile, AbbVie quietly raised its 2026 outlook on the strength of Skyrizi and Rinvoq growth in immunology and neurology, while management described itself as having “ample financial capacity” for M&A. And J.P. Morgan published its Q1 deal report: medtech M&A totaled $26.6 billion across 37 deals, a figure that rivals biopharma deal volume and has been underreported relative to its significance.
Top Story: Novo Launches Oral Ozempic — The Most Calculated Brand Play of the Year
What Happened: Novo Nordisk began selling oral Ozempic (semaglutide tablets) in more than 70,000 U.S. pharmacies on Monday May 4. The product is a rebrand of Rybelsus, Novo’s existing oral semaglutide for type 2 diabetes that has been available since 2019, now sold under the Ozempic name in three new dosages (1.5 mg, 4 mg, and 9 mg). Novo has also filed with the FDA for a 25 mg label expansion, with a decision expected by the end of 2026.
Why the Ozempic Name Changes Everything
Rybelsus has been available since 2019 but never achieved the commercial traction of injectable Ozempic. The molecule is identical—semaglutide—but the brand recognition gap is enormous. Ozempic is one of the most well-known drug brands in the world, propelled by years of direct-to-consumer advertising, cultural conversation, and the explosive growth of the GLP-1 category. Rybelsus, despite being the same molecule in oral form, never broke through to mainstream consumer awareness.
By putting the Ozempic name on the pill, Novo is betting that brand recognition will drive adoption in a way that Rybelsus never could. When a patient asks their doctor about “Ozempic” and learns there is now a pill version, the conversation is fundamentally different than when a doctor tries to introduce “Rybelsus” as an oral alternative. The Ozempic brand carries trust, familiarity, and cultural momentum that no amount of Rybelsus marketing could replicate.
This is not just a label change. It is a strategic repositioning of Novo’s entire oral T2D franchise under a brand that patients already know and physicians already trust.
The Pricing: Designed to Maximize Adoption
The pricing structure is aggressive and transparently competitive with Lilly’s Foundayo:
Insured patients: As low as $25 for a three-month prescription. That is lower than most co-pays for branded diabetes drugs and positions oral Ozempic as the most accessible branded oral GLP-1 for insured patients.
Cash-pay patients: $149 per month for the starter dose through select telehealth providers including WeightWatchers and GoodRx. This matches Foundayo’s $149 per month self-pay entry price exactly.
The pricing parity at the self-pay level means the competitive battle between oral Ozempic and Foundayo in the T2D market will be fought on convenience (Foundayo has no fasting requirement versus oral Ozempic’s 30-minute fasting window), brand recognition (Ozempic’s massive consumer awareness versus Foundayo’s newer brand), and physician familiarity (most physicians already prescribe injectable Ozempic and are comfortable with the molecule).
U.S. Manufacturing: Tariff-Proofing the Oral Franchise
The oral Ozempic pills are manufactured entirely in the United States. This is strategically significant for two reasons. First, it insulates the oral franchise from Section 232 tariff exposure. Novo’s injectable products are manufactured in Denmark, making them subject to the 15% tariff rate under the EU bilateral trade agreement. Having the oral franchise manufactured domestically means Novo avoids tariff costs entirely on what could become a major revenue driver.
Second, domestic manufacturing is a talking point that matters for formulary negotiations. Pharmacy benefit managers and health plans that are concerned about supply chain risk—a concern that has intensified since the Section 232 tariff framework was announced—will view a domestically manufactured product more favorably than an imported one.
The Competitive Landscape: Foundayo Now Faces Three Novo Products
With the oral Ozempic launch, Lilly’s Foundayo now competes against three distinct Novo oral and injectable products:
Oral Ozempic for type 2 diabetes ($25 insured, $149 cash-pay). Direct competitor to Foundayo’s upcoming T2D indication. Same molecule as injectable Ozempic but in pill form.
Oral Wegovy for obesity ($149 per month at lower doses, launched January 2026). Direct competitor to Foundayo’s current obesity indication. Has a three-month head start in market development.
Injectable Wegovy for obesity (subscription pricing $249 to $329 per month, plus standard self-pay at $349). The established injectable franchise competing with Zepbound.
Foundayo’s advantages remain its dosing convenience (no food or water restrictions, take any time of day) and the ACHIEVE-4 data package (cardiovascular safety and the 57% all-cause mortality signal). Novo’s advantages are brand recognition (Ozempic and Wegovy are among the most recognized drug names globally), physician familiarity with the semaglutide molecule, the three-month obesity head start with oral Wegovy, and now aggressive insured-patient pricing on oral Ozempic ($25 versus Foundayo’s $25 insured copay).
Our Pro brief analyzes why the Ozempic rebrand could reshape the oral T2D market, how the pricing positions against Foundayo across insured and self-pay channels, and what U.S. manufacturing means for tariff-proofing the oral franchise. [Details below.]
What to Watch
Novo’s Q1 earnings dropping this morning will provide the first read on how effectively the company is executing across its oral portfolio. Oral Wegovy revenue will be the headline number. The oral Ozempic launch occurred too late in Q1 (May 4) to contribute to Q1 results, but management commentary on early uptake and the commercial strategy will be important. The 25 mg label expansion filing decision expected by end of 2026 could unlock the higher-dose market and strengthen oral Ozempic’s competitive position against higher-dose Foundayo tiers.
AbbVie Raises 2026 Outlook on Immunology and Neurology Growth
What Happened: AbbVie raised its full-year 2026 outlook after reporting strong Q1 growth in immunology and neurology. Skyrizi and Rinvoq continue to grow faster than Humira is declining. Neuroscience assets are contributing meaningful revenue. Management highlighted “ample financial capacity” for future M&A.
Why This Matters
AbbVie’s raised outlook is significant because it demonstrates that the Humira patent cliff—the most-watched patent event in pharmaceutical history—is being successfully navigated. Humira was the world’s best-selling drug for nearly a decade. Biosimilar competition began in earnest in January 2023. AbbVie’s strategy of building Skyrizi and Rinvoq as next-generation immunology replacements has worked: the combined growth of the two drugs is outpacing Humira’s decline, producing net growth for the immunology franchise.
The “ample financial capacity” language is forward-looking. AbbVie has already entered the KRAS oncology space through its $1.45 billion Kestrel option deal. The raised outlook and explicit M&A capacity commentary suggest AbbVie has both the balance sheet and the confidence to make a larger acquisition in the second half of 2026. For business development teams at clinical-stage biotechs, AbbVie’s statement is a signal to engage.
Our Pro brief analyzes how Skyrizi/Rinvoq growth is outrunning Humira decline and what “ample financial capacity” signals for the M&A pipeline. [Details below.]
MedTech M&A Hits $26.6B in Q1: The Underreported Story
What Happened: J.P. Morgan published its Q1 2026 biopharma and medtech deal report. The medtech figures are striking:
Medtech M&A: $26.6 billion across 37 deals. Medtech venture funding: $2.2 billion across 66 rounds. Medtech IPO activity: One IPO raising $600 million on Nasdaq.
Biopharma comparisons from the same report: M&A totaled $15.6 billion across 19 deals (using J.P. Morgan’s narrower definition). Licensing reached $77.3 billion in announced value. Venture funding totaled $5.2 billion. Six biopharma IPOs raised $1.8 billion, already surpassing full-year 2025 proceeds.
Why Medtech M&A Deserves More Attention
The biopharma M&A wave has dominated headlines—and this newsletter—throughout 2026. But medtech M&A is running at a comparable pace in dollar terms and deserves equivalent attention.
The drivers are similar to biopharma: technology transitions (robotic surgery, AI diagnostics) are creating consolidation opportunities. The Commerce Department’s active Section 232 investigation into medical devices—with the report expected later this month—is creating urgency for companies to build domestic manufacturing capacity before potential tariffs take effect. Scale advantages in manufacturing, distribution, and regulatory infrastructure are pushing smaller device companies toward acquisitions by larger players.
The Section 232 report on medical devices, expected later this month, is the next major policy catalyst for medtech. If the Commerce Department recommends tariffs on imported devices using the same tiered structure as the pharmaceutical tariffs (high baseline rate, reduced rates for onshoring, exemptions for cooperators), the medtech M&A pace could accelerate further as companies rush to build domestic manufacturing capacity or acquire companies that already have it.
The biopharma licensing figure of $77.3 billion in announced value—with upfront cash representing just 6% of total deal value—illustrates how the licensing market has evolved. The gap between announced value and upfront cash reflects the heavy use of milestones, CVRs, and royalty structures that shift risk from the acquirer to the target company. For biotech companies evaluating whether to license their assets versus pursue acquisition or IPO, the 6% upfront realization rate is a critical data point.
The IPO market continues to strengthen: six biopharma IPOs raising $1.8 billion in Q1 already surpasses full-year 2025 proceeds. Combined with the medtech IPO (one company at $600 million), the total life sciences IPO market is on pace for its strongest year since the pandemic-era boom.
For business development teams and investors: medtech M&A deserves as much attention as biopharma in 2026. The deal volume is comparable, the drivers are similar, and the regulatory catalyst (Section 232) could create a new wave of urgency.
Novo Q1 Earnings: What Drops This Morning
Novo Nordisk Q1 2026 earnings release at 7:00 AM EST with a conference call to follow. This is the most anticipated pharma earnings report remaining in the quarter.
The key numbers: First official oral Wegovy revenue (launched January 2026). Ozempic and Wegovy injectable revenue trends. GLP-1 supply chain commentary. BALANCE delay impact assessment. Foundayo competitive read. 2026 guidance update. Oral Ozempic launch commentary (though too late for Q1 contribution).
We will cover the full results in detail in tomorrow’s email.
Strategic Themes
1. The Ozempic Rebrand Is a Masterclass in Brand Leverage
Novo took an existing product that has been on the market since 2019, gave it a new name, three new dosages, and aggressive pricing, and created the most significant oral T2D commercial event of the year. The molecule did not change. The clinical data did not change. What changed was the brand—and in consumer healthcare, brand recognition is the single most powerful driver of adoption. By putting the Ozempic name on the pill, Novo turned a solid performer into a potential blockbuster and created a direct competitive weapon against Foundayo in the oral T2D segment.
2. Foundayo Now Faces a Three-Product Novo Assault
Lilly’s Foundayo must compete against oral Ozempic (T2D), oral Wegovy (obesity), and injectable Wegovy (obesity) simultaneously. No other company has deployed three distinct GLP-1 products against a single competitive entry. Foundayo’s convenience advantage remains meaningful, but Novo’s brand recognition, physician familiarity, pricing aggressiveness, and multi-product strategy create a competitive challenge that goes well beyond any single head-to-head comparison.
3. AbbVie’s Humira Cliff Navigation Should Be Required Reading for Every Pharma CFO
AbbVie is raising its outlook despite losing the most successful pharmaceutical product in history to biosimilar competition. The strategy—build next-generation replacements (Skyrizi, Rinvoq) before the cliff hits, invest in new therapeutic areas (neuroscience, oncology), and maintain M&A capacity for the next growth catalyst—is working. For Merck, BMS, Novartis, and every other company facing a patent cliff, AbbVie is the template.
4. Medtech M&A at $26.6B Is Running in Parallel to the Pharma Wave
The device sector is consolidating at a pace that rivals biopharma. The Section 232 medical device investigation, technology transitions in robotic surgery and AI diagnostics, and scale-driven competitive dynamics are producing deal flow that has received far less attention than it deserves. The Commerce Department report expected later this month could be the catalyst that moves medtech M&A from a parallel trend to a front-page story.
Frequently Asked Questions
What is oral Ozempic?
A rebrand of Rybelsus (oral semaglutide for T2D, available since 2019) under the Ozempic name in three new dosages (1.5 mg, 4 mg, 9 mg). Launched in 70,000+ U.S. pharmacies on May 4. Insured patients pay as low as $25 for a three-month supply. Cash-pay patients pay $149 per month starter dose through telehealth providers. A 25 mg label expansion filing decision is expected by end of 2026.
Why rebrand Rybelsus as Ozempic?
Ozempic is one of the most recognized drug brands in the world. Rybelsus, despite being the same molecule, never achieved comparable consumer awareness. By putting the Ozempic name on the pill, Novo is betting that brand recognition will drive adoption that Rybelsus marketing could not achieve. The timing—two days before Q1 earnings—is clearly strategic.
How does oral Ozempic pricing compare to Foundayo?
Both are $149 per month at the self-pay starter dose. For insured patients, oral Ozempic is as low as $25 for three months. Foundayo’s insured copay is as low as $25 per month. The pricing structures are designed for competitive parity at the entry level, with the battle fought on convenience, brand recognition, and physician familiarity.
Why does U.S. manufacturing matter for oral Ozempic?
Oral Ozempic is manufactured entirely in the United States, which insulates it from Section 232 tariff exposure. Novo’s injectable products are manufactured in Denmark and face the 15% EU tariff rate. Domestic manufacturing also strengthens formulary negotiations with PBMs concerned about supply chain risk.
What did AbbVie report?
AbbVie raised its 2026 outlook on strong growth in immunology (Skyrizi, Rinvoq) and neurology. Management highlighted “ample financial capacity” for M&A, notable given AbbVie’s recent entry into the KRAS oncology space through the $1.45 billion Kestrel option deal.
What does the J.P. Morgan deal report show for medtech?
Medtech M&A totaled $26.6 billion across 37 deals in Q1 2026. Venture funding was $2.2 billion across 66 rounds. One medtech IPO raised $600 million. Biopharma comparisons: M&A at $15.6 billion (narrower definition), licensing at $77.3 billion, six IPOs raising $1.8 billion (surpassing full-year 2025 proceeds).
When does Novo report Q1 earnings?
This morning (May 6). The 7:00 AM EST conference call will deliver the first official oral Wegovy revenue, injectable franchise trends, BALANCE delay commentary, and 2026 guidance. Full coverage in tomorrow’s email.
What is the SCOTUS mifepristone timeline?
Briefs are due tomorrow (May 7). Justice Alito’s administrative stay expires May 11. The full Court will then decide whether to extend the stay, let the 5th Circuit ruling take effect, or take the case on the merits.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
The Ozempic Rebrand: Brand Leverage in Action. We analyze why putting the world’s most famous drug name on a pill could reshape the oral T2D market, how the pricing architecture positions against Foundayo across insured and self-pay segments, and what U.S. manufacturing means for tariff-proofing the oral franchise.
AbbVie’s Cliff Navigation Playbook. We break down how Skyrizi/Rinvoq growth is outrunning Humira decline, what the raised outlook implies for full-year performance, and why “ample financial capacity” signals that AbbVie is preparing for a larger M&A move in H2 2026.
Medtech M&A: The $26.6B Story No One Is Talking About. We analyze why medtech deal volume rivals biopharma, how the Section 232 device investigation is accelerating consolidation, and which device categories and companies are most likely to drive the next wave of transactions.
Plus: Novo Q1 earnings preview, SCOTUS mifepristone timeline, biopharma IPO market dynamics, and the updated catalyst calendar through ASCO and H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
